Peptide Supplements and the FDA: What Manufacturers Need to Document Before the Rules Catch Up
The peptide supplement market is growing fast and operating in a regulatory space that the FDA has not fully defined — which sounds like good news until you understand what happens to manufacturers in grey-zone categories when enforcement ramps up.
BPC-157, TB-500, ipamorelin, CJC-1295, and dozens of other research peptides are being sold openly as supplements, research chemicals, and wellness products. The demand is enormous. The margins are attractive. And the documentation practices at many manufacturers producing these products are, frankly, not where they need to be when a regulatory agency decides it's time to look closely at the category.
This post is not about whether peptide supplements are legal. That question has a complicated answer that varies by compound, claim, and intended use. This post is about what manufacturers in this space need to have documented — right now, regardless of where the regulatory lines eventually settle — to protect themselves when scrutiny arrives.
What the Semaglutide Crackdown Actually Signaled
In late 2024, the FDA moved against compounding pharmacies producing semaglutide copies, declaring the shortage over and directing compounders to stop producing the drug. The crackdown was specific to pharmaceutical compounding, but the signal it sent was broader: when a peptide category becomes large enough to attract public attention, the FDA moves.
Peptide supplements occupy a different legal space than compounded drugs. But the pattern is consistent across the history of FDA enforcement in supplements: grey-zone categories grow, attract bad actors who make egregious claims or cut corners on quality, and eventually draw regulatory attention that lands on everyone in the category — including the manufacturers who were doing things reasonably well.
What differentiates the manufacturers who survive that scrutiny from those who don't is almost never the product itself. It is the documentation.
Why Peptide Manufacturers Face Unique Documentation Challenges
Peptides are not vitamins. The documentation challenges that come with manufacturing peptide supplements are more demanding than most categories, for several reasons.
Stability and degradation
Peptides are sensitive. Temperature excursions during shipping or storage can degrade active compounds without any visible change to the product. If a stability concern is raised — by a consumer complaint, a third-party lab test, or an FDA inquiry — your batch records need to show the storage conditions for each lot from receiving through finished goods. Without that documentation, you cannot demonstrate that a potency issue was a supplier problem rather than a manufacturing or storage problem.
Potency verification at the lot level
Peptide raw materials have real lot-to-lot variability in purity and potency. A COA from your supplier is a starting point, not a guarantee. Manufacturers who are adjusting batch quantities based on actual lot assay values — and documenting those adjustments in their batch records — are in a fundamentally stronger position than those running fixed quantities against a nominal specification.
This matters both for quality and for regulatory positioning. If your finished product is tested and comes back under label claim, the question is: did you verify incoming potency and adjust accordingly? If the answer is yes and you have the batch records to prove it, you have a defensible position. If the answer is no, you don't.
Source and identity documentation
Peptide raw materials often originate from suppliers in countries with varying quality control standards. Country of origin, supplier identity, and chain of custody documentation are relevant both for quality assurance and for the kind of records an FDA investigator will request. If you cannot trace a specific lot of raw material back to its source and demonstrate what testing was done on it, you have a traceability gap that cannot be reconstructed after the fact.
The "research use only" documentation challenge
Many manufacturers in the peptide space sell products labeled for research use only. This is a legal positioning that has its own documentation requirements — and its own risks if the actual consumer use and marketing language don't support that positioning. Whatever your legal strategy, your batch records need to reflect consistent product specifications, manufacturing controls, and testing. "Research use only" labeling does not create an exemption from good manufacturing practice.
The Four Records That Actually Matter When the FDA Comes Knocking
Experience with FDA inspections and Warning Letters in the supplement industry shows that investigators typically focus on a predictable set of documentation when they are concerned about product quality or compliance.
1. Incoming material records with COA linkage
For every lot of raw material, inspectors will want to see: who the supplier is, what testing was done on the incoming material, what the COA shows, and how the results were reviewed before the material was approved for production. A filing cabinet of COAs that are not linked to specific production batches is not useful documentation — it is paperwork.
The standard that protects you is COA documentation linked at the lot level to the production batches that used that material. When an investigator asks "which batches were made with lot number X," you should be able to answer in seconds, not hours.
2. Batch records with actual vs. theoretical quantities
A complete batch record shows not just what the formula calls for, but what was actually weighed, by whom, when, and verified by a second operator. Theoretical quantities on a master formula sheet are not batch records. The actual quantities used in a specific production run, documented in real time, are what the FDA considers a batch record.
For peptide products, this is particularly important because the quantities involved are often small — milligram-level actives where a weighing error creates a meaningful potency deviation. A batch record that shows who weighed what and what scale was used is the documentation that demonstrates manufacturing control.
3. Finished product testing results linked to batch records
If you test finished products — which you should, and which is increasingly expected for peptide products given the category's visibility — those test results need to be linked to specific batch numbers, not stored as a separate file. An investigator who pulls a complaint for lot number X needs to be able to find the test results for that lot without a research project.
4. Deviation and out-of-spec records
Manufacturing never goes perfectly. The question is whether deviations are documented and resolved, or whether they disappear into informal conversations and never appear in your records. Any production run where something didn't go to plan — a scale calibration issue, an out-of-spec yield, a raw material that came in slightly under specification — should have a documented deviation record showing what happened, how it was evaluated, and what the disposition decision was.
Manufacturers with no deviation records often have more deviations than manufacturers with many. The ones with records are the ones demonstrating actual quality oversight.
What Happens to Manufacturers Who Wait
The pattern in FDA enforcement is consistent and has played out across categories that were once grey zones — prohormones, SARMs, certain herbal products marketed for weight loss.
Phase one: the category grows and most manufacturers operate without close scrutiny. Phase two: a high-profile incident — a serious adverse event, a third-party lab exposé, a competitor making egregious drug claims — brings investigative attention to the category. Phase three: enforcement actions begin, and they are not limited to the bad actors. Warning Letters and import alerts reach manufacturers who were operating in the grey zone without adequate documentation, even if their products were not the ones that triggered the inquiry.
The manufacturers who come through this phase without significant disruption are the ones whose documentation could withstand a full inspection on any given day. Not because they anticipated the specific enforcement action, but because they built documentation practices that are defensible by default.
Building those practices before phase two arrives is significantly easier than building them under regulatory pressure. And the window for doing it proactively — before peptide supplements are the subject of the same level of enforcement attention that SARMs eventually received — may be shorter than it looks.
How Batch Buddy Supports Peptide Manufacturers Specifically
Batch Buddy was built for manufacturers who need FDA-grade documentation without a pharmaceutical-scale quality team.
The features that matter most for peptide manufacturers:
Lot-level traceability from raw material to finished goods. Every production run is linked to the specific raw material lots used. A traceability search returns the complete chain — supplier, lot number, COA, production batch, finished goods, and shipment — in seconds. This is the documentation structure that makes a targeted recall possible and an FDA inquiry manageable.
Potency tracking and automatic quantity adjustment. When you receive a lot with an actual assay value different from the nominal specification, Batch Buddy records the actual value and automatically calculates adjusted ingredient quantities for production runs using that lot. The adjustment is documented in the batch record. Your finished product hits spec. The calculation is auditable.
Real-time batch record documentation. Operators document what was actually done during production — actual quantities, lot numbers, operator identity, timestamps — as it happens. By the time the batch is complete, the record is complete. There is no reconstruction from memory or post-production paperwork.
FDA 21 CFR Part 11 compliant audit trail. Every record creation, edit, and approval is logged with user identity, timestamp, and before/after values. Records cannot be deleted. Changes cannot be made without appearing in the audit log. This is the standard that makes your documentation defensible under regulatory review.
The Documentation Is Cheaper Before You Need It
The cost of building solid batch record practices now is a few hours of setup and a workflow adjustment for your production team. The cost of building them after an FDA inquiry, a consumer complaint that goes public, or a third-party lab test that finds your product under label claim is measured in legal fees, potential recall costs, lost retailer relationships, and reputational damage that follows the brand for years.
The peptide supplement category is not going to stay under the regulatory radar indefinitely. The manufacturers who will be positioned to grow through the next phase of enforcement attention are the ones who treated documentation as a competitive advantage rather than a compliance burden.
That starts with batch records. And it starts before you need them.
Batch Buddy provides FDA 21 CFR Part 11 compliant batch records, lot-level traceability, and potency tracking for supplement manufacturers. Start your 14-day free trial and run your first documented production batch this week.